ASP-1893 / Astellas - LARVOL DELTA

A Study of ASP1893 in Adults With Advanced CLDN6-positive Solid Tumors (clinicaltrials.gov) - P1 | N=0 | Withdrawn | Sponsor: Astellas Pharma Global Development, Inc. | N=197 ➔ 0 | Not yet recruiting ➔ Withdrawn

Enrollment change • Metastases • Trial withdrawal • Endometrial Cancer • Genito-urinary Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Ovarian Cancer • Solid Tumor • Testicular Cancer